Stock Taper
SCREENER COMPARE ANY 2 STOCKS
WGS
GENEDX HOLDINGS CORP.
NASDAQ
$85.99
▼ DOWN 1.60% (-1.40)

KEY STATISTICS

Market Cap$2.56 B
52w High$170.87
52w Low$32.21
Dividend Yield—
Frequency—
P/E238.86
Volume304.28K
Shares Out.29.82M

COMPANY

LEADERSHIP

Katherine A. Stueland
CHIEF EXECUTIVE
Katherine A. Stueland

COMPENSATION 2026

Salary$715,869
Stock Awards$11,738,600
Incentive Plan Pay$1,075,500
All Other Comp.$17,250
Total$13,547,219

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 4, 2020
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
1,300

PRICE TARGET

Target High$90.00
Target Low$63.00
Target Median$80.00
Target Consensus$79.50

UPCOMING EARNINGS

DateOct 27, 2026
DayTuesday
Rev. Est.$122.98M
OCT
27
TUE

SPLIT RECORD

DATETYPERATIO
2023-05-04Reverse1:33

PRICE

$85.99 ▼ DOWN 1.60% (−$1.40)
OVERLAYS
$84.00$85.50$87.009:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM85.99

About GeneDx Holdings Corp.

http://www.genedx.com ↗

GeneDx Holdings Corp., founded by Eric Schadt in 2015, uses AI and machine learning on clinical and genomic data via its Centrellis platform to deliver personalized health insights and advance disease understanding.

INDUSTRY

Medical - Diagnostics & Research

A PRODUCT GENEDX HOLDINGS CORP. IS KNOWN FOR

ExomeDx™
ExomeDx™

ExomeDx™ is an FDA Breakthrough Device-designated whole exome sequencing test by GeneDx that identifies genetic causes of rare diseases, enhancing diagnosis for patients with unexplained symptoms.

COMPETITORS

COMPETITOR
FLGT COMPARE
GH COMPARE
MYGN COMPARE
NTRA COMPARE
PSNL COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Diagnostic Test$113.52M $117.56M ▲$101.3M ▼$111.89M ▲
Diagnostic Test Third Party Insurance$95.02M $101.05M ▲$84.92M ▼$94.73M ▲
Diagnostic Test Institutional Customers$17.87M $16.21M ▼$16.09M ▼$16.12M ▲
Product and Service Other$3.22M $3.43M ▲$955K ▼$2.55M ▲
Diagnostic Test Self Pay$629K $297K ▼$286K ▼$1.04M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
133
LISTED HERE
26
RANKED BY POSITION SIZE
ARKK
1.26% · 955.7K
VTI
0.00% · 607.8K
IWM
0.06% · 515.2K
TSME
1.98% · 201.3K
SCHA
0.04% · 104.0K
DFAS
0.05% · 97.4K
FESM
0.10% · 76.8K
XHS
2.59% · 65.8K
FYC
0.17% · 27.4K
FSML
1.32% · 23.2K
GSSC
0.17% · 20.6K
GNOM
1.73% · 18.4K
XRSU.L
0.06% · 17.8K
PRFZ
0.03% · 9.1K
BBSC
0.09% · 7.2K
NUSC
0.03% · 5.1K
EZM
0.02% · 2.5K
ETLZ.DE
0.08% · 2.0K
RFLR
0.09% · 1.1K
URTY
0.02% · 787
GPT
0.28% · 764
WCEO
0.52% · 715
STXK
0.07% · 681
ESSC
0.15% · 629
TILT
0.00% · 501
SSMG
0.38% · 140

INSTITUTIONAL OWNERSHIP

SHARES OWNED
71.63%
HOLDERS
386
TOP 12 OF 386 · RANKED BY POSITION SIZE
Corvex Management LP
4.8M sh · $328.46M
Casdin Capital, LLC
3.7M sh · $254.5M
Blackrock, Inc.
1.7M sh · $117.13M
Goldman Sachs Group Inc
1.7M sh · $114.61M
Ark Investment Management LLC
1.6M sh · $110.54M
William Blair Investment Management, LLC
1.4M sh · $96.15M
Westfield Capital Management Co LP
1.4M sh · $87.92M
Vanguard Group Inc
1.2M sh · $154.65M
Franklin Resources Inc
1.1M sh · $142.15M
Morgan Stanley
988.3K sh · $67.85M
Blackrock Inc.
924.6K sh · $24.17M
Summit Partners Public Asset Management, LLC
920.6K sh · $119.73M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
Feeley Kevin
Purchase · 717 shares
2026-09-01
★
OFFICER: CHIEF FINANCIAL OFFICER
Feeley Kevin
Sale · 372 shares
2026-09-01
★
OFFICER: CHIEF FINANCIAL OFFICER
Feeley Kevin
Sale · 717 shares
2026-09-01
★
OFFICER: PRESIDENT
GARDNER MARK A
Purchase · 35.4K shares
2026-06-29

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OVERWEIGHT 2
5 GRADES IN THE LAST 12 MONTHS
Canaccord Genuity BUY BTIG BUY Guggenheim BUY Piper Sandler OVERWEIGHT Wells Fargo OVERWEIGHT

SECTORS PEERS

PEERPRICE
KYMR$117.63COMPARE
CRNX$84.95COMPARE
OSCR$32.27COMPARE
IMVT$39.45COMPARE
HNGE$92.52COMPARE
VKTX$34.64COMPARE
OPCH$24.16COMPARE
TMDX$88.28COMPARE